Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal vein leiomyosarcoma

E D Gierson, J H Rowe

    The American Surgeon
    |August 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    This case study details the third instance of renal vein leiomyosarcoma, a rare cancer. Early detection and surgical removal offer hope, but adjunctive chemotherapy may improve survival rates for this retroperitoneal tumor.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hypomorphic <i>Rag1</i> mutations alter the preimmune repertoire at early stages of lymphoid development.

    Blood·2018
    Same author

    Results from a multidisciplinary breast center. Analysis of disease discovered.

    Surgical oncology clinics of North America·1997
    Same author

    Intraductal breast carcinoma: experiences from the Breast Center in Van Nuys, California.

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·1996
    Same author

    Extended skin island delay of the unipedicle TRAM flap: experience in 35 patients.

    Plastic and reconstructive surgery·1995
    Same author

    Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability.

    Journal of the American College of Surgeons·1995
    Same author

    Prognostic classification of breast ductal carcinoma-in-situ.

    Lancet (London, England)·1995
    Same journal

    Complete Response of Merkel Cell Carcinoma to Immunotherapy and Single-Fraction Radiotherapy Following Severe COVID-19 Infection: A Case Report and Review of Immune Mechanism.

    The American surgeon·2026
    Same journal

    Perioperative Acute Myocardial Infarction in Non-Cardiac Operations: A National Analysis.

    The American surgeon·2026
    Same journal

    Outcomes of Completion Cholecystectomy: Association With Patient Comorbidity in a National Database.

    The American surgeon·2026
    Same journal

    Building the Conversation: Editorial Stewardship in Contemporary Surgical Publishing.

    The American surgeon·2026
    Same journal

    Musculoskeletal Pain in Surgeons on Operating Days.

    The American surgeon·2026
    Same journal

    Splenectomy During Cytoreductive Surgery: Marker of Surgical Burden or Independent Predictor of Morbidity?

    The American surgeon·2026
    See all related articles

    Area of Science:

    • Urology
    • Surgical Oncology
    • Vascular Surgery

    Background:

    • Leiomyosarcoma is a rare malignant mesenchymal tumor.
    • Retroperitoneal leiomyosarcomas have a poor prognosis, with a 2-year survival rate of 20% in other locations.
    • Renal vein leiomyosarcoma is exceptionally rare, with only two prior reported cases.

    Observation:

    • The third case of renal vein leiomyosarcoma is presented.
    • Diagnosis was established during exploratory celiotomy, identifying a tumor originating from the left renal vein.
    • Surgical resection with clear margins of normal vein was performed.

    Findings:

    • The patient remained alive and recurrence-free 12 months post-operation.
    • This contrasts sharply with the low survival rates observed for leiomyosarcomas in other retroperitoneal structures.

    Related Experiment Videos

    Implications:

    • Complete surgical resection is crucial for favorable outcomes.
    • Postoperative adjunctive chemotherapy should be considered for renal vein leiomyosarcoma to improve patient survival.
    • Further research into optimal treatment strategies for this rare malignancy is warranted.